Company Filing History:
2 out of 1,744 
2 out of 5,089 
2 out of 34 
Years Active: 2023-2024
Title: Innovations in Cancer Diagnosis and Treatment: The Work of Kim In-San
Introduction
Kim In-San, a distinguished inventor based in Seoul, South Korea, has made significant contributions to the field of medical diagnostics and treatment. With two patents to his name, he is at the forefront of innovative methods for assessing and treating pancreatic ductal adenocarcinoma (PDAC), a challenging form of cancer.
Latest Patents
Kim's latest patents focus on an early and non-invasive method for assessing the risk of pancreatic ductal adenocarcinoma in individuals. His innovative approach involves measuring the level of βig-h3 protein in blood samples, which has been found to positively correlate with the risk of developing PDAC. Through rigorous studies on two distinct cohorts—comprising 20 and 104 PDAC patients—as well as a PDAC mouse model, Kim demonstrated that βig-h3 can be directly detected in blood samples and is expressed early in tumorigenesis within pancreatic neoplastic lesions. Additionally, his research delves into the use of antagonists of βig-h3 protein in treating PDAC. The findings indicate that βig-h3 binds directly to CD8T cells, reducing their activation and cytotoxic properties. Notably, using neutralizing βig-h3 antibodies in mouse models led to a reduction in tumor growth by enhancing the anti-tumoral response of CD8T cells. This breakthrough positions βig-h3 as a novel immunological checkpoint target, to restore beneficial anti-tumor immunity in PDAC patients.
Career Highlights
Throughout his career, Kim In-San has been associated with notable research institutions, including the Institut National De La Santé Et De La Recherche Médicale and the Centre National De La Recherche Scientifique. His experience in these esteemed organizations has not only bolstered his expertise but has also paved the way for groundbreaking research in the field of oncology.
Collaborations
Kim's collaborative efforts with prominent researchers, such as Philippe Bertolino and Ana Hennino, underscore the importance of teamwork in advancing medical science. These partnerships have facilitated the exchange of ideas and expertise, contributing to significant progress in the understanding and treatment of PDAC.
Conclusion
Kim In-San's innovative work in developing non-invasive methods for diagnosing and treating pancreatic ductal adenocarcinoma highlights his dedication to improving patient outcomes. His research represents a pivotal shift in cancer diagnostics, emphasizing the importance of early detection and targeted treatment strategies in the ongoing battle against cancer. With continued collaboration and innovation, Kim's contributions may lead to more effective therapies and improved prognoses for those affected by PDAC.